TLC

Taiwan Liposome Company Ltd.

Price

return (12m)

p/e

0.00

p/bv

0.00

DIVIDEND YIELD

0.00%

TLC price

Taiwan Liposome Company

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment TLC

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals TLC

Valuation

P/E

0.00

Sector -4.26

Industry -4.26

P/BV

0.00

Sector 2.11

Industry 2.11

P/Revenue (PSR)

Sector 2.08

Industry 2.08

EV/EBITDA

Sector -546.19

Industry -546.19

EV/EBIT

Sector -37.31

Industry -37.31

P/EBITDA

Sector -50.76

Industry -50.76

P/EBIT

Sector -39.62

Industry -39.62

P/Total Assets

Sector 1.25

Industry 1.25

P/Net Current Assets

Sector -5.47

Industry -5.47

P/Working Capital

Sector -1.10

Industry -1.10

EPS

Sector -1.94

Industry -1.94

BVPS

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

0.00%

Sector 38.90%

Industry 38.90%

EBITDA Margin

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

0.00%

Sector -36.74%

Industry -36.74%

Net Profit Margins

0.00%

Sector -37.51%

Industry -37.51%

Asset Turnover

Sector 0.03

Industry 0.03

Profitability

ROE

Sector -61.50%

Industry -61.50%

ROA

Sector -63.85%

Industry -63.85%

ROIC

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

Sector 2.89

Industry 2.89

Net Debt / EBITDA

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

Sector -10.24

Industry -10.24

Net Debt / Equity

Sector -0.60

Industry -0.60

Gross Debt / Equity

Sector -0.83

Industry -0.83

Equity/Assets

Sector 0.43

Industry 0.43

Liabilities/Assets

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals TLC

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
TLC Taiwan Liposome Company Ltd.	$0.00	-	0.00%	0.00	0.00	0.00%	0.00%
JNJ Johnson & Johnson	$270.50	56.19%	1.93%	31.09	7.70	24.76%	21.48%
PFE Pfizer Inc.	$28.30	22.58%	6.26%	35.86	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$262.90	30.71%	2.58%	74.16	-78.93	-106.44%	9.81%
NVO Novo Nordisk A/S	$47.19	-12.22%	3.95%	11.47	6.09	53.11%	35.32%
MRK Merck & Co. Inc.	$153.10	86.45%	2.24%	116.78	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$166.27	6.54%	1.93%	24.59	5.10	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.57	50.14%	3.73%	14.81	6.16	41.55%	18.85%
ZTS Zoetis Inc.	$77.52	-48.92%	2.67%	12.20	10.25	84.02%	27.77%
REGN Regeneron Pharmaceuticals Inc.	$823.41	40.89%	0.44%	19.71	2.69	13.65%	27.86%
AMGN Amgen Inc.	$442.24	55.97%	2.22%	27.25	20.39	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$108.20	49.84%	0.00%	30.73	88.55	288.14%	24.86%
MCK McKesson Corporation	$896.65	32.75%	0.38%	19.60	-26.88	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$547.29	40.71%	0.00%	31.57	6.87	21.76%	35.00%
CAH Cardinal Health Inc.	$238.40	65.33%	0.88%	35.20	-20.39	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.66	5.99%	0.00%	12.32	2.23	18.14%	18.89%
BIIB Biogen Inc.	$221.07	62.12%	0.00%	38.68	1.71	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

TLC Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Taiwan Liposome Company

Taiwan Liposome Company Ltd.

Average Investor10 user rating

4.0 (1 people)

United States

29 years

Founded: 1997

2018

Time since IPO - 8 years

-

Employees

Taiwan Liposome Company Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $-, with shareholders equity totaling $-.

The Company is listed on the [MARKET_NAME]

Over the past 12 months, Taiwan Liposome Company Ltd. reported $- in revenue, generating net income of $-.

Key financial metrics include a P/E ratio of 0.00, a price-to-book (P/B) ratio of 0.00, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker TLC.

Market cap

Net worth

Assets

Total Shares Outstanding

42.08 million

42,077,000

Average Daily Trading Volume

$15.06 Thousand

$15,058.44

Sector

Health Care

Industry

Biotechnology

TLC

TLC revenue and profits

Financial Results TLC

DRAG THE FRAME TO SEE MORE DATA

TLC cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$896.65 31,86% (12M)

P/E

19.60

0.38%

ROE

-137.16%

P/BV

-26.88

CAH - Cardinal Health

$238.40 61,79% (12M)

P/E

35.20

0.88%

ROE

-57.93%

P/BV

-20.39

JNJ - Johnson & Johnson

$270.50 57,62% (12M)

P/E

31.09

1.93%

ROE

24.76%

P/BV

7.70

ABBV - AbbVie

$262.90 30,39% (12M)

P/E

74.16

2.58%

ROE

-106.44%

P/BV

-78.93

MRK - Merck & Co.

$153.10 89,20% (12M)

P/E

116.78

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$166.27 6,46% (12M)

P/E

24.59

1.93%

ROE

20.74%

P/BV

5.10

PFE - Pfizer

$28.30 22,92% (12M)

P/E

35.86

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$896.65 31,86% (12 M)

P/L

19.60

0.38%

ROE

-137.16%

P/VP

-26.88

CAH - Cardinal Health

$238.40 61,79% (12 M)

P/L

35.20

0.88%

ROE

-57.93%

P/VP

-20.39

JNJ - Johnson & Johnson

$270.50 57,62% (12 M)

P/L

31.09

1.93%

ROE

24.76%

P/VP

7.70

ABBV - AbbVie

$262.90 30,39% (12 M)

P/L

74.16

2.58%

ROE

-106.44%

P/VP

-78.93

MRK - Merck & Co.

$153.10 89,20% (12 M)

P/L

116.78

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$166.27 6,46% (12 M)

P/L

24.59

1.93%

ROE

20.74%

P/VP

5.10

PFE - Pfizer

$28.30 22,92% (12 M)

P/L

35.86

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Taiwan Liposome Company (TLC) today?

A cotação de Taiwan Liposome Company (TLC) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Taiwan Liposome Company (TLC) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Taiwan Liposome Company (TLC) e dados de ações do Ibovespa e mercados internacionais.

Quando Taiwan Liposome Company (TLC) paga dividendos?

Taiwan Liposome Company (TLC) não distribuiu dividendos no último ano.

Is Taiwan Liposome Company (TLC) a good investment?

Atualmente, Taiwan Liposome Company (TLC) está cotada a US$ 0.00, com um P/L de 0.00, representando um desvio de 0% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Taiwan Liposome Company (TLC) stock?

Investir em ações de Taiwan Liposome Company (TLC) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Taiwan Liposome Company (TLC) yield today?

A rentabilidade de Taiwan Liposome Company (TLC) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Taiwan Liposome Company (TLC) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

TLC

Taiwan Liposome Company Ltd.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment TLC

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING TLC WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Taiwan Liposome Company

Taiwan Liposome Company Ltd.

United States

29 years

2018

-

PROFIT X PRICE TLC

Financial Results TLC

TLC cash flow

Asset, Revenue and Profit Growth - TLC

TLC balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions